(SYBX) Synlogic, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SYBX) Synlogic, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Synlogic, Inc. BCG Matrix provides a clear view of how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs, helping with strategy, research, and capital allocation. The content on this page is a real preview of the actual report, so you can see the format and quality before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
0 approved products
As of end-2025, Synlogic, Inc. had 0 approved or marketed products, so the Stars quadrant is empty.
There was no commercial leader with high share in a growing market, and 2025 revenue from approved products was 0.
So Synlogic, Inc. had no Star asset to fund growth or defend market share.
0 commercial brands
Synlogic, Inc. had 0 commercial brands in its BCG Stars bucket because its portfolio never reached commercial stage. Its programs were clinical-stage only, so there was no brand with broad adoption, sales scale, or a defended market position. In its last public filings, Synlogic reported no product revenue, which keeps Stars at zero.
0 recurring product revenue
Synlogic, Inc. had no approved product, so recurring product revenue was $0 in the latest fiscal year. That means the business did not match a Star asset, which should combine fast revenue growth with ongoing capital use. With no sales base to scale, Synlogic’s pipeline stayed in the development stage, not the recurring-revenue stage.
0 market-share leaders
Synlogic’s named programs were all still in development, so there was no sold product and no addressable commercial market to capture. That makes the company a clear 0 market-share leader in BCG terms. In its latest reported period, Synlogic still had no product revenue, so market share was effectively zero.
- No approved, sold product
- No commercial market share
- All named programs were development-stage
- Latest product revenue: 0
Pre-commercial pipeline only
Synlogic, Inc. was an R&D-led biotech with a pre-commercial pipeline, so it had no meaningful product sales to support a BCG Star. Its value depended on future clinical wins, not current market share or cash generation, which makes the profile high risk and still speculative.
No commercial revenue base
Depends on trial success
Not a Star today
Synlogic Had No BCG Stars in 2025
Synlogic, Inc. had no Stars in 2025: it had 0 approved products, 0 product revenue, and no commercial market share. Its portfolio stayed clinical-stage, so there was no fast-growing, cash-generating brand to place in BCG Stars.
| Metric | 2025 |
|---|---|
| Approved products | 0 |
| Product revenue | $0 |
| Star assets | 0 |
What is included in the product
Detailed Word Document
Synlogic, Inc. BCG Matrix maps its pipeline across Stars, Cash Cows, Question Marks, and Dogs to guide invest/hold/divest decisions.
Editable Excel File
One-page Synlogic, Inc. BCG Matrix to quickly spot quadrant shifts and reduce strategy guesswork
Reference Sources
Provides a credible source trail for Synlogic, Inc., helping users verify claims quickly and make more confident decisions.
Cash Cows
0 mature franchises
Synlogic had 0 mature franchises and no approved drug, so it had no cash cow in the BCG sense. Cash cows need stable sales and high share in an established market, but Synlogic remained a clinical-stage biotech with no product revenue in its latest filing. No such asset was identified.
0 approved therapies
Synlogic, Inc. had 0 approved therapies in FY2025/FY2026, so it had no marketed drug generating dependable cash flow. With no approved asset to "milk," the cash-cow bucket stayed empty. That also meant no recurring product revenue to offset R&D burn or support the business.
0 royalty stream
Synlogic, Inc. had no identified product royalty base in its core portfolio, so its Cash Cows royalty stream was 0. Cash cows usually come from late-life brands or royalty lines that keep generating steady cash, but Synlogic did not disclose one. In FY2025/FY2026 terms, that means no royalty income to support the BCG matrix cash-cow slot.
0 steady operating margin
Synlogic, Inc. was not a cash cow: it had no meaningful sales engine, so there was no steady operating margin to turn revenue into free cash flow. In its latest reported period, the business was still funding R&D and overhead from cash reserves, which is the opposite of the low-capital, high-margin profile a cash cow needs.
- No durable sales base.
- Cash burn funded development.
- No strong free cash flow.
0 low-growth commercial asset
Synlogic had 0 low-growth commercial assets because it had no marketed products and was still pursuing clinical proof-of-concept across programs. In its latest filings, revenue stayed at 0, so this BCG Cash Cow quadrant had no fit. The model was all R&D, not harvest.
- No commercial product base
- Revenue remained 0
- Pipeline still in proof-of-concept
Synlogic Had No Cash Cows in FY2025/FY2026
Synlogic, Inc. had no Cash Cows in FY2025/FY2026. It reported no approved therapies, no marketed products, and no product revenue, so there was no stable cash-generating asset to harvest. The BCG Cash Cow slot stayed empty because the business was still funding R&D from cash reserves.
| Metric | FY2025/FY2026 |
|---|---|
| Approved therapies | 0 |
| Product revenue | 0 |
| Cash cows | 0 |
Preview Before You Purchase
Synlogic, Inc. Reference Sources
The Synlogic, Inc. BCG Matrix preview you’re viewing is the exact same file you’ll receive after purchase. No watermarks, no demo pages—just the complete, professionally formatted report. Once purchased, the full document is yours for immediate download and use. What you see here is what you get.
Dogs
100% clinical-stage company
Synlogic, Inc. was 100% clinical-stage, with 0 commercial products and no sales engine. That meant the Company relied on outside funding to cover R&D and G&A costs, while near-term cash return stayed near zero. In BCG terms, this fit the Dog slot: high cash use, weak monetization, and limited strategic payoff.
0 launched assets
Synlogic, Inc. sits in Dogs with 0 launched assets, so it has no approved product sales to fund operations. That means development spend must be paid before any cash comes back, and in the latest public filings product revenue remained $0. In BCG terms, this is a clear value drag unless the pipeline can turn into a launch.
R&D-funded model
Synlogic's R&D-funded model depended on outside capital, not product sales, and the company had no product revenue in its latest filings. That made returns hinge on approval, while R&D kept burning cash before any payoff. In BCG terms, that is classic Dogs: low return, high burn, and weak near-term cash flow.
No scale manufacturing sales
Synlogic, Inc. had no scaled commercial manufacturing sales, so this was not a cash-generating Dog. Its oral and intratumoral programs were still in clinical trials, and the company reported no product revenue in its last filings, with R&D spending still consuming cash. Without a proven sales base or manufacturing scale, the asset base never behaved like a winner.
- No scaled revenue stream
- Programs still in trials
- No winner economics without scale
High clinical failure risk
Synlogic, Inc. fits Dogs because each clinical asset carried phase-transition, FDA, and funding risk, while clinical biotechs can burn $20M to $100M+ a year before any sales. When programs stall, the odds of write-downs rise fast, and that is why low-traction assets get tagged as Dogs in BCG analysis. The company still had to fund trials, manufacturing, and review work with no commercial cushion.
- Phase risk stays high
- Cash burn hits before revenue
- Regulatory delays can kill value
- Funding risk compounds failure
Synlogic: All Risk, No Revenue
Synlogic, Inc. fits Dogs because it had 0 product revenue, no approved assets, and still had to fund clinical work and overhead before any cash came back. With no commercial cushion, value depended on risky trial success, not existing sales.
| Metric | Value |
|---|---|
| Product revenue | 0 |
| Commercial assets | 0 |
| Stage | Clinical-only |
Question Marks
SYNB1618 Phase II PKU
SYNB1618 was Synlogic, Inc.'s most advanced asset: an oral, non-systemically absorbed synthetic biotic in Phase II for phenylketonuria, a rare disease seen in about 1 in 23,000 to 1 in 50,000 births. It had 0 commercial sales and no market share. So it fits the Question Mark quadrant: high upside if data land well, but high trial risk and no cash flow yet.
SYNB1934 Phase II PKU
SYNB1934 was Synlogic, Inc.'s oral, non-systemically absorbed Phase II candidate for phenylketonuria, a rare disease affecting roughly 1 in 15,000 to 1 in 25,000 newborns. It sits in the Question Marks bucket because it targets the same high-value orphan market, but clinical-stage risk is still real. If it had shown strong efficacy and safety, it could have moved Synlogic, Inc. toward a leadership position in PKU.
SYNB1353 homocystinuria
SYNB1353 for homocystinuria fits the Question Mark bucket: it was built as an oral, non-systemic therapy for a rare disease with clear unmet need, but Synlogic had not shown commercial traction. Homocystinuria affects only a small patient pool, so even strong clinical data would face a limited market. That makes the asset high-potential, but still unproven.
SYNB8802 Phase I enteric hyperoxaluria
SYNB8802 was an oral, non-systemic Phase I asset for enteric hyperoxaluria, so it sat in the highest-uncertainty, highest-upside corner of Synlogic, Inc.'s BCG matrix. Phase I usually means first-in-human testing, with small cohorts and no proof of efficacy yet. That makes it a textbook Question Mark: promising science, but no clear market fit or cash flow.
- Phase I: early clinical risk
- Oral, non-systemic design
- High upside, no sales proof
- Classic Question Mark
SYNB1891 Phase I oncology
SYNB1891 was a Question Mark for Synlogic, Inc.: an intratumorally delivered synthetic biotic medicine in Phase I for solid tumors and lymphoma, so it had high oncology upside but no proven share yet. Phase I meant the asset was still early, with 0 commercial sales and no clear path to scale at that stage. Its value was future optionality, not current market power.
- Phase I only, so high risk.
- Oncology offers large upside.
- No market share yet.
Synlogic’s High-Risk, High-Reward Pipeline Bets
Synlogic, Inc.'s Question Marks were all early-stage, pre-revenue bets: SYNB1618, SYNB1934, and SYNB1353 in Phase II, SYNB8802 and SYNB1891 in Phase I. They targeted rare-disease or oncology niches with high upside, but none had commercial sales or proven market share, so each depended on trial success to create value.
| Asset | Stage | BCG fit |
|---|---|---|
| SYNB1618 | Phase II | Question Mark |
| SYNB1934 | Phase II | Question Mark |
| SYNB1353 | Phase II | Question Mark |
| SYNB8802 | Phase I | Question Mark |
| SYNB1891 | Phase I | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.